Softbank-backed Neumora's depression drug cuts symptoms in mid-stage trial : vimarsana.com

Softbank-backed Neumora Therapeutics' experimental drug navacaprant has helped reduce symptoms of depression in patients with moderate-to-severe forms of the disorder in a mid-stage trial, the company said on Tuesday.

Related Keywords

Bengaluru , Karnataka , India , United States , American , Henry Gosebruch , Vaibhav Sadhamta , Paul Berns , Raghav Mahobe , Pooja Desai , Thomson Reuters Trust Principles , Reuters , Softbank Vision Fund , Neumora Therapeutic , Blackthorn Therapeutics , Thomson Reuters Trust , Rsbi Regulatory Oversight , Rhpi Corporate Structure , Rhpi Drug Device Trials , Rhpi Regulatory , Bact , Biz , Cmpny , Depres , Drudev , Gen , Genhlt , Hea , Headmi , Heca , Humdis , Indgwh , Inds , Inds08 , Iser , Iser08 , Medreg , Mentil , Mngiss , Mrch , Mrch1 , Painmg , Phag08 , Phar , Phar08 , Phar1 , Phmr , Privt , Psycho , Publ , Regs , Sci , Tcom , Tech , Tech08 , Tel , Tmt , Trad08 , Wles , Wles1 , Easia , Amers , Swasia , Us , Meast , Tglf , Namer , Asxpac , Ae , Asia , Jp , Man ,